10-Q: Shattuck Labs Reports First Quarter 2024 Financial Results and Provides Business Update

Shattuck Labs reports a net loss of $18.5 million for the first quarter of 2024, alongside updates on its clinical programs and a new collaboration agreement.

Summary

• Shattuck Labs, a clinical-stage biotechnology company, reported a net loss of $18.5 million for the three months ended March 31, 2024, compared to a net loss of $20.7 million for the same period in 2023.
• The company's collaboration revenue increased significantly to $1.1 million in Q1 2024, up from $0.1 million in Q1 2023, primarily due to a new agreement with Ono Pharmaceutical Co., Ltd.
• Research and development expenses decreased slightly to $16.3 million in Q1 2024 from $16.7 million in Q1 2023, mainly due to a decrease in manufacturing costs offset by increased clinical trial expenses.
• General and administrative expenses also saw a slight decrease, falling to $4.9 million in Q1 2024 from $5.1 million in Q1 2023.
• As of March 31, 2024, Shattuck Labs had $114.6 million in cash, cash equivalents, and investments, which the company believes is sufficient to fund operations into 2026.
• The company's accumulated deficit stood at $324.8 million as of March 31, 2024.
• Shattuck Labs is focused on advancing its lead product candidate, SL-172154, through ongoing clinical trials for ovarian cancer and certain hematologic malignancies.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company shows progress in revenue and clinical trials, it continues to operate at a loss and faces significant risks. The sentiment is neutral, reflecting both positive developments and ongoing challenges.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Collaboration revenue saw a substantial increase, demonstrating the potential of the company's technology and partnerships.
• Shattuck's cash position is strong, providing a runway into 2026.
• The Ono collaboration provides significant funding and potential future milestone payments.
• The company is actively advancing its clinical programs, with multiple ongoing trials for SL-172154.

Negatives

• Shattuck Labs continues to operate at a loss, with a net loss of $18.5 million for the quarter.
• The company has an accumulated deficit of $324.8 million, highlighting its ongoing need for funding.
• Research and development expenses remain high, reflecting the costly nature of drug development.
• The company is dependent on a limited number of contract manufacturers and research organizations, which could pose a risk to operations.

Risks

• The company is subject to risks related to the timing and results of clinical trials, regulatory approvals, and commercialization of product candidates.
• Shattuck Labs may need to raise additional capital in the future, which may not be available on acceptable terms or at all.
• The company faces competition from other biotechnology companies developing similar therapies.
• Global economic instability, including inflation and supply chain issues, could negatively impact the company's operations.
• The company is dependent on a limited number of contract manufacturers and research organizations, which could pose a risk to operations.

Future Outlook

The company expects to continue to incur significant expenses and operating losses in the near term as it advances its product candidates and expands its pipeline. Shattuck believes its current cash and investments are sufficient to fund operations into 2026.

Management Comments

• Management believes that the Companys cash and cash equivalents and investments of $114.6 million as of March 31, 2024 are sufficient to fund projected operations of the Company for at least the next twelve months from the date of filing of these financial statements.
• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Industry Context

The collaboration with Ono Pharmaceutical Co., Ltd. highlights the growing interest in dual-sided fusion proteins for autoimmune and inflammatory diseases, a competitive area in the biotechnology industry. The company's focus on novel immune modulation approaches positions it within the broader trend of developing innovative cancer therapies.

Comparison to Industry Standards

• Shattuck's Q1 2024 net loss of $18.5 million is within the range of losses reported by other clinical-stage biotech companies at a similar stage of development.
• The increase in collaboration revenue to $1.1 million is a positive sign, as many early-stage biotech companies rely heavily on such partnerships for funding.
• The company's cash runway into 2026 is relatively strong compared to some peers, providing a longer period to achieve key milestones.
• The company's R&D expenses of $16.3 million are typical for a company with multiple ongoing clinical trials.
• Compared to companies like Xencor and MacroGenics, which also focus on antibody engineering, Shattuck's collaboration with Ono is a significant step in validating its technology platform.

Stakeholder Impact

• Shareholders may be concerned about the ongoing losses but encouraged by the collaboration agreement and clinical progress.
• Employees may be affected by the company's financial performance and future funding needs.
• Customers and suppliers may be impacted by the company's ability to commercialize its products.
• Creditors may be concerned about the company's accumulated deficit and future funding requirements.

Next Steps

• Continue to advance the nonclinical and clinical development of SL-172154.
• Manufacture sufficient quantities of drug substance and drug product to support ongoing and planned studies.
• Continue process development efforts for current and future product candidates.
• Initiate nonclinical studies and clinical trials for additional product candidates.
• Maintain operational, financial, and management systems.
• Continue to develop, perfect, and defend the intellectual property portfolio.

Key Dates

Keywords

Shattuck Labs, Biotechnology, Clinical Trials, SL-172154, Oncology, Immunotherapy, Collaboration Agreement, Ono Pharmaceutical, Financial Results, Research and Development